Real-time impedance monitoring: a simple technique for a complex ablation.

E. Daoud

DOI: https://doi.org/10.1016/J.HRTHM.2005.07.001

IF: 6.779

2005-09-01

Heart Rhythm

Abstract:

What problem does this paper attempt to address?

Exploration of Effect and Dosage of Botulinum Toxin Type A for Long-Term Treatment of Idiopathic Blepharospasm

胡兴越,蔡华英,邵宇权

DOI: https://doi.org/10.3969/j.issn.1007-7669.2004.01.011

2004-01-01

Abstract:AIM: To explore the relationship between the efficacy and the dosage of botulinum toxin type A (BTXA) for long-term and repetitive treatment of blepharospasm. METHODS: 178 patients repetitively treated with BTXA were followed up for 7 a. The dosage, effect, effect duration, and adverse reations of 6 sessions were compared among themselves. The severity of blepharospasm was gauged by Cohen scale. SAS software package was administered for statistic analysis. RESULTS: 178,138,112,83,63, and 48 patients were enrolled in the consequently 6 sessions in 7 a. The withdraw rates were 14.0 %(25/178) (P0.05),5.1 %(7/138), 5.4 %(6/112),6 %(5/83) and 6 %(4/63) since the second session. The effective rate of each session was 89.9 %(160/178),97.1 %(134/138),96.4 %(108/112),95 %(79/83),95 %(60/63), and 98 %(47/48), respectively. The average BTXA dosage was about 70 U, and the mean duration of improvement was 15-16 wk. Though the lower effective rate in the first session compared with the second and third sessions, there were no significant differences among other sessions in the effective rate, mean dosage and duration of improvement. The incidence rates of adverse reactions were 36.5 %(65/178),31.9 %(44/138),31.3 %(35/112),31 %(26/83),30 %(19/63) and 29 %(14/48) respectively in each session, and there were no significant differences in statistic analysis. The adverse reactions of focal weakness occurred at 2-3 d after effect emerged and lasted 2-6 wk. The most concerned complications were ptosis, blurred vision and diplopia. The ptosis occurred 10.1 % in the first session, which had statistic difference (P0.05) compared with the second and third sessions (3.6 %-3.6 %). The adverse reaction rate was 30 % on the whole. CONCLUSION: Without increasing dose, the long-term therapeutic effect and duration of improvement can be maintained by repeated topical BTXA injection. The incidence of adverse reactions such as ptosis can be reduced.
Clinical Observation of Treatment with Botulinum Toxin A for the Ipsilateral Tinnitus in Hemifaciai Spasm Patients

HU Xing-yue,GE Ding-fei

2006-01-01

Abstract:Objectives To observe the efficacy of local injection of botulinum toxin A for ipsilateral tinnitus in hemifacial spasm(HFS)patients.Methods 194 cases of HFS with ipsilateral tinnitus were treated and followed during seven and half years.The diagnosis of ipsilateral tinnitus was made according to clinical manifestation.The factors of the patients' with/without ipsilateral tinnitus and the response to botulinum toxin A(BTXA)were compared,statistical data were eval- uated by SAS software package.Results The symptom completely or obviously relieved in 33.51%(65/194)patients with BTXA treating.In the other 129 patients with poor response to BTXA treatment,101 patients had severe tinnitus while only 36 patients have severe tinnitus in 65 patients (P＜0.01).Conclusion One-fourth HFS patients are accompanied with ipsilateral tinnitus.One-third patients may get clinical relief with BTXA local injections.It seems that the patients with mild spasm and mild tinnitus can achieved good response.
The Effect of Botulinum Neurotoxin A Injections on Meibomian Glands and Dry Eye

Ali Sawaed,Shakad Noah Friedrich,Abed Farhan,Aseel Nassar,Mira Hamed,Morris Hartstein,Shirin Hamed Azzam

DOI: https://doi.org/10.1016/j.jtos.2024.11.009

IF: 6.268

2024-12-01

The Ocular Surface

Abstract:Purpose To assess the influence of Botulinum neurotoxin A (BoNT-A) injection on meibomian gland function and dry eye in patients diagnosed with Blepharospasm (BPS) and Hemifacial spam (HFS). Methods Adult patients aged 18 years or older who suffer from periocular dystonia, and were treated with BoNT-A injections, were recruited in this interventional prospective study between 2023 and 2024. Each patient was followed up for a period of three months. The following parameters were compared at baseline, 14 and 90 days post BoNT-A injections: Visual acuity, meibography, tear break up time (TBUT), Schirmer test, meibum expression, tear meniscus height, fluorescein corneal staining, meibomian gland dysfunction (MGD) grading, and ocular surface disease index (OSDI). In addition, patients underwent subjective quality of life questionnaire for BPS and HFS. Results Thirty-six eyes of twenty-six patients were included in this study. The mean age ± SD was 59 ± 17.33 years. There was a significant statistical difference in vascular changes on the lid margin, TBUT, corneal and conjunctival fluorescein staining and meibum expression (P<0.001 in all). The differences were statistically significant when compared to baseline vs visit 2, and visit 2 vs visit 3 (p-value<0.05). Jankovic rating scale and HFS score improved significantly between the time periods (P<0.001 in both).There was no significant difference in meibomian gland loss, tear meniscus height, Schirmer test, and OSDI. Conclusion BoNT-A injection is an effective treatment for periocular dystonia, but it worsens ocular surface and dry eye disease. Moreover, it affects the meibomian glands by disturbing their secretion.

ophthalmology
Improved Spiking Cortical Model Based Algorithm for Multi-focus Image Fusion

W. Kong,Yang Lei

DOI: https://doi.org/10.1007/978-3-319-67777-4_45

2017-09-22

Abstract:
Ocular Surface Alterations in Blepharospasm Patients Treated with Botulinum Toxin a Injection

Sibel Kocabeyoglu,Hande Taylan Sekeroglu,Mehmet C. Mocan,Ersin Muz,Murat Irkec,Ali Sefik Sanac

DOI: https://doi.org/10.5301/ejo.5000482

2014-01-05

European Journal of Ophthalmology

Abstract:Purpose To evaluate ocular surface changes secondary to periocular botulinum toxin A injection in patients with essential blepharospasm. Methods Thirteen eyes of 13 patients with essential blepharospasm who underwent periocular botulinum toxin A injection were included in this prospective study. Patients were evaluated prior to and at 2-week and 1-, 3-, and 6-month time points following injections. Ocular surface tests were carried out in the order of tear break-up time (TBUT), lissamine green (LG) staining, Schirmer I test with anesthesia, and ocular surface disease index (OSDI) questionnaire for all patients. The Friedman test with Conover post hoc method was used for statistical comparisons of values at different time points. Results The TBUT was found to be increased at 1 month after the injection (8.5 ± 2.1; p = 0.018) and decreased below baseline levels (6.4 ± 2.1) at the 6-month visit (5.7 ± 2.0; p = 0.018). None of the Schirmer test values at follow-up visits were significantly different as compared to baseline levels (11.3 ± 5.5), although the 2-week measurement (14.3 ± 5.6) was significantly higher as compared to that at the 6-month follow-up visit (9.6 ± 4.9; p = 0.034). There was also a significant decrease in LG staining scores at 2-week (0.6 ± 0.4; p = 0.012) and 1-month (0.6 ± 0.4; p = 0.012) time points compared to the baseline levels (1.1 ± 0.6). The OSDI scores improved at 2-week (5.4 ± 6.8; p<0.001), 1-month (3.2 ± 5.1; p<0.001), 3-month (2.5 ± 4.4; p<0.001), and 6-month (5.5 ± 5.4; p<0.001) time points as compared to baseline levels (11.6 ± 8.5). Conclusions Botulinum toxin A injection appears to have a positive but temporary effect on ocular surface parameters in patients with blepharospasm.

ophthalmology
Treatment Effects of Botulinum Toxin Injection and Acupuncture on Blepharospasm Assessed by the Change in Lower Eyelid Tension

Fang-Fang Bao,Qing-Song Li,Zhen-Yong Zhang,Min-Hong Xiang

DOI: https://doi.org/10.1080/02713683.2019.1578379

Abstract:Objective: To investigate the treatment effects of botulinum toxin-A (BTA) injection and acupuncture on blepharospasm (BP) evaluated by the change in lower eyelid tension (LET). Methods: A series of 30 patients (male: 8, female: 22) aged between 37 and 83 years (63.80 ± 10.96 yrs) who met the eligibility criteria of BP were recruited in this study, who were randomly assigned to BTA injection group (BTA group, n = 15) and acupuncture treatment group (Acupuncture group, n = 15). BTA injections were administered to the patients in BTA group while patients in acupuncture group received the acupuncture treatment. The LET was measured by a tensiometer in both groups at baseline and at post-treatment. Results: A significant decrease in LETs over 8 weeks was found in acupuncture group (812.76 ± 193.95 Pa at baseline, 549.69 ± 150.04 Pa at 4 weeks, and 510.96 ± 150.66 Pa at 8weeks, respectively; F = 31.127, p << 0.001). There was a significant decrease in LET from 858.61 ± 190.54 Pa at baseline to 414.45 ± 63.38 Pa at 2 weeks after treatment (Z = -4.542, p << 0.01) in BTA group. At the endpoint of the study, a significant difference in LET was found between the acupuncture group (301.80 ± 181.77 Pa) and the BTA group (444.16 ± 193.44 Pa) (t = -2.077, p = 0.047). Conclusions: BP patients have an increased LET. Both BTA and acupuncture are effective in decreasing the LET. Close monitoring of LET holds promise in planning the treatment strategy for Blepharospasm.
Study of the effect of botulinum toxin on electrophysiological monitoring during microvascular decomp-ression surgery for patients with hemifacial spasm

Ning JIANG,Wei-bang LIANG,Wu XU,Jing WANG

DOI: https://doi.org/10.12037/YXQY.2016.11-23

2016-01-01

Abstract:Objective To investigate the effect of botulinum toxin on electrophysiological monitoring during microvascular decompression surgery for patients with hemifacial spasm (HFS). Method A retrospective analysis was conducted on 121 patients who hospitalized in our hospital because of HFS from November 2014 to April 2015. They were divided into botulinum toxin group (30 cases) and non-botulinum toxin group (91 cases) according to preoperative ipsilateral acceptance of botulinum toxin. Botulinum toxin group patients received 3 ~ 12 injection treatment of botulinum toxin. Intraoperative electrophysiological monitored mandibular branch, zygomatic branch latency and amplitude of two groups and the incidence of complications were compared between the two groups. After 1-year follow-up, symptom relief of the patients were evaluated, and the electric physiological monitoring results were compared between remission as well as non-remission patients and botulinum toxin group as well as non-botulinum toxin group. Result The lateral spread response (LSR) latency of zygomatic branch of facial nerve in non-botulinum toxin group was significantly shorter than botulinum toxin group (P < 0.05); there was no significantly associated to the prognosis of whether the electrophysiological monitoring of marginal mandibular branch of the facial nerve disappearing alone and the marginal mandibular branches with electrophysiological monitoring disappear at the same time or not (P >0.05); patients inbotulinum toxin group zygomatic electrophysiology disappearing alone and non-botulinum toxin group patients whose zygomatic electrophysiology without disappeared were poor prognosis (P < 0.05). Conclusion Botulinum toxin can effectively delay zygomatic LSR latency, and the zygomatic disappearance of LSR can effectively predict the prognosis, which is more obvious in patients injected botulinum toxin.
Non-surgical treatment of 150 cases of blepharospasm and hemifacial spasm

Suyan ZHAO

DOI: https://doi.org/10.3760/cma.j.issn.1674-845X.2009.03.019

2009-01-01

Abstract:Objective To observe the efficacy of using Botox-A in the treatment of blepharospasm(BS) and hemifacial spasm(HFS).Methods A total of 150 patients with BS and HFS were involved in the present study.Fifty patients who had the disease for less than six months were divided into two groups:one group(25 cases) was treated with a local ice-bag application and the other group(25 cases) was used for the control.One hundred patients who had a history of more than 6 months were managed with a local injection of Botox-A.Results In the 25 patients treated with ice bags,symptoms completely disappeared in 23 patients and the remaining 2 patients presented with relieved spasm.Among the 25 cases used as the controls,the symptoms of 15 patients spontaneously disappeared 1 to 2 months later,7 patients presented with relieved spasm and the conditions of 3 patients remained unchanged.Ninety-eight of the 100 cases with BS and HFS whose history lasted more than 6 months had a complete or obvious remission of symptoms after receiving a local injection of Botox-A(BTA),with no effect seen after the treatment in the remaining 2 cases.No systemic toxic or side effects were found in any patients treated with a Botox-A injection.Conclusion Local ice-bag application contributes to the relief of BS and HFS in the early stages.A BTA local injection,which is easy to administer,is a safe,effective and reliable treatment for patients whose spasm has lasted for more than 6 months.
Correlation Between Blepharospasm and Psychological Diseases: the Anxiety, Depression and Sleep Disorder Study

Hui-Na Zhang,Qi Gao,Jia-Jun Xie,Juan Ye

DOI: https://doi.org/10.18240/ijo.2024.11.05

IF: 1.645

2024-01-01

International Journal of Ophthalmology

Abstract:AIM: To investigate the relationship between benign essential blepharospasm (BEB) symptoms and depression/anxiety/sleep disorder in a prospective manner and to determine whether treatment the BEB with botulinum toxin type A (BoNT/A) can impact psychological symptoms. METHODS: This prospective interventional case series recruited 61 adults with evidence of BEB. Patients were administered the Jankovic Rating Scale (JRS), the Blepharospasm Disability Index (BSDI), Personal Health Questionnaire Depression Scale (PHQ-8), Generalized Anxiety Disorder 7-item scale (GAD-7) and the Athens insomnia scale (AIS) to evaluate the severity of BEB symptoms, depression, anxiety and sleep disorder before and 1wk, 1, 3mo after the BoNTA treatment. Statistical analysis was performed to assess the relationships between changes in the survey scores. RESULTS: The mean score for JRS, BSDI, PHQ-8, and GAD-7 improved significantly (P<0.0001), respectively, compared to the initial visit at follow-up. At baseline, worse BSDI scores were correlated with worse GAD-7 and PHQ-8, but not with worse AIS. At 1mo follow-up visit, there was no correlation between change in BSDI and PHQ-8/AIS, the change in GAD-7 showed a mild association with change in BSDI. The change in BSDI was correlated with the change in both PHQ-8 and GAD-7 in the subgroup of patients without a prior diagnosis of depression or anxiety. Patient satisfaction with BoNT/A treatment reached the highest at 1mo of follow-up (83.6%, 51/61). CONCLUSION: BEB may lead to psychological diseases. BoNT/A can significantly improve motor and non-motor symptoms of BEB, which emphasize the effectiveness of BoNT/A and therefore pave the way for its use in the field of psychiatry. However, further research is needed to confirm these findings and understand the underlying mechanisms.
Increasing the area and varying the dosage of Botulinum toxin a injections for effective treatment of hemifacial spasm

Won Joo Choe,Jin Kim

DOI: https://doi.org/10.3109/00016489.2016.1165864

Abstract:Conclusion: Wider-area botulinum toxin (BT) injection with the dosage depending on specific pathology is a promising approach for the treatment of hemifacial spasm (HFS), resulting in effective and long-lasting control of HFS with fewer side-effects. Objective: The aim of this study was to develop a BT injection strategy that minimizes complications by considering the causes, duration, and electrophysiologic features of the disease, as well as the patient's age. Methods: From July 2011 to July 2015, 26 patients were included in the strategy. The mean age was 61.8 ± 14.6. In the case of essential HFS, 2 units/injection site was the standard dosage. If a patient was aged over 60 and had a reduced electromyogram (EMG) amplitude, the dosage was reduced by 0.5 units/site. In the case of post-paralytic and tumor-induced HFS, 1.5 units/site was the standard dosage. All cases were managed by alternating injections of Botox and Dysport with no physical therapy. Results: Most HFS patients treated with the injection strategy had complete remission of HFS within 1 week. The average number of BT injection sites was 22.6 ± 6.7. The mean total BT dosage on the affected side was 28.6 ± 4.9 units. The mean duration of BT efficacy was 28.6 ± 7.7 weeks.
Evaluation of the effect of botulinum toxin A on the physical and mental health of patients with hemifacial spasm

J S Wei,X Hu,L Xia,J Shang,Q Han,D Y Zhang

DOI: https://doi.org/10.1016/j.nrleng.2024.07.001

Abstract:Background: Hemifacial spasm (HFS) is a debilitating disease characterized by involuntary tonic and clonic contractions of muscles innervated by the facial nerve. Botulinum toxin A (BTX-A) is the first-line option and the most effective medical treatment for HFS. The objective of this study was to evaluate the effect of BTX-A therapy on the physical and mental health of HFS patients. Methods: Participants included 65 HFS patients and 65 matched healthy controls in the study. Cornell Medical Index (CMI) self-assessment questionnaire was used to detect the psychological health of all participants. Local injection of BTX-A was applied, and the Cohen hierarchical criteria were employed to stratify the degree of spasticity, further evaluating the efficacy of BTX-A before and two months after treatment in HFS patients. The HFS patients at two months post-treatment were re-evaluated by CMI self-assessment questionnaire, and the evaluated factors of these patients were compared with those of patients before treatment. Results: The scores of somatization, depression, anxiety, inadaptation, sensitivity, anger, tension, M-R, and total scores in the HFS group were significantly higher than those in the control group (all P<0.05). Two months post-treatment, among 65 HFS patients who received with BTX-A treatment, 42 (64.6%) were completely relieved, 16 (24.6%) were significantly relieved, 7 (10.8%) were partially relieved, and 0 (0%) cases were invalid, and the total effective rate was 89.2%. Two months after BTX-A treatment, the scores of somatization, tension, anxiety, depression, sensitivity, M-R and total scores of patients with HFS were lower than those before treatment (all P<0.05). Conclusions: Patients with HFS are often accompanied by somatization, anger, inadaptation, sensitivity, anxiety, depression, and tension. BTX-A can not only alleviate the symptoms of HFS, but also improve the somatization, tension, anxiety, depression, and sensitivity.
Remote F - wave changes after local botulinum toxin type A application

Yuyu HU,Xingyue HU

DOI: https://doi.org/10.13558/j.cnki.issn1672-3686.2007.01.007

2007-01-01

Abstract:Objective To evaluate the remote F-wave and excitability of the spinal motoneurons changes after local intramuscular administration of botulinum toxin type A.Methods Botulinum toxin type A was injected into neck muscles of 29 patients with idiopathic torticollis spasmodicus.The latency and persistence of F-waves of the ulnar nerve and the tibial nerve were recorded bilaterally and compared immediately before(time 0) and 1 and 12～16 weeks after the injections.Results The amplitude,the latency and conductive velocity of the M-waves of the ulnar nerves and the tibial nerves were unchanged at times 1 week and 12～16 weeks after BTX-A injection.The latency of the F-waves of the ulnar nerves and the tibial nerves were prolonged significantly at times 1 week(P<0.05) and recovered 12～16 weeks after BTX-A injection.The persistence of the F-waves were unchanged at times 1 week and 12～16 weeks after BTX-A injection.No significant correlation of the change of latency was found with the spreading distance and the used dosage of BTX-A.Conclusion It proposes the remote effects after local BTX-A application.The remote F-wave latency is prolonged and the excitability of remote spinal motoneurons is decreased after local BTXA application.No significant correlation of the changes of F-wave was found with the used dosage and spreading distance of BTX-A.Possibly,its pathophysiological mechanism is very complex,and many causes are involved.
Botulinum Toxin Injection with Conjunctival Microincision for the Treatment of Acute Acquired Comitant Esotropia and Its Effectiveness

Hongjia Xu,Weifeng Sun,Shuying Dai,Yanyan Cheng,Jing Zhao,Yuan Liu,Juan Wang,Ya’nan Wang,Yu Gao,Huifang Han,Aijun Han

DOI: https://doi.org/10.1155/2020/1702695

2020-12-31

Journal of Ophthalmology

Abstract:Purpose. To report on an improved botulinum toxin injection with conjunctival microincision for beginners, and to determine the effectiveness of botulinum toxin A (BTXA) in the treatment of patients with acute acquired comitant esotropia (AACE). Methods. Medical records of 29 AACE patients were retrospectively analyzed. BTXA was injected into the unilateral or bilateral medial rectus muscle with conjunctival microincision without electromyographic guidance. Success was defined as total horizontal deviation ≤10 prism diopters (PD) and evidence of binocular vision. Results. Twenty-nine patients were included, of whom 22 were male and 7 were female. The mean age at onset was 14.2 ± 7.4 (range, 4–34) years. The mean time from onset of AACE to injection was 18.4 ± 20.3 (range, 1–96) weeks. All patients completed at least 6 months of follow-up, and the mean follow-up after BTXA injection was 12.3 ± 4.8 months (range, 7–24 months). Neurological evaluation and brain magnetic resonance imaging (MRI) were unremarkable in all patients. The mean spherical equivalent refraction was −1.22 ± 2.85D and −0.97 ± 2.80D in the right and left eyes, respectively. Mean preinjective esotropia was 38.4 ± 18.9 PD (range, +10–+80 PD) at near and 40.2 ± 17.7 PD (range, +20–+80 PD) at far distance. The mean angle of deviation at 6 months after injection was 0.6 ± 4.1 PD (range, −3–+15 PD) at near and 3.0 ± 5.9 PD (range, 0–+20 PD) at far distance. There was significant difference in the angle of deviation at near and far fixation between pre-BTXA and post-BTXA 6 months ( p < 0.001 , p < 0.001 , resp.). There was no significant difference in the angle of deviation at near and far fixation between post-BTXA 6 months and post-BTXA at final follow-up ( p = 0.259 and 0.326, resp.). Mean stereoacuity improved from 338 to 88 arc seconds. During the follow-up period, 5 of 29 patients had recurrent esotropia. Two patients refused all further treatment, and the other 3 patients required incisional strabismus surgery. The success rates were 86.2% (25/29) at 6 months and 82.8% (24/29) at final follow-up. Conclusion. Conjunctival microincision injection of botulinum toxin is a practical and safe method for beginners to locate an extraocular muscle, which is as effective as the traditional methods. Botulinum toxin injection can be preferred as the first-line treatment for AACE patients with potential binocular vision.

ophthalmology
Objective Assessment of the Repeated Botox Treatment to the Synkinesis of Facial Paralysis by the Integrated Electromyography

Tsutomu Homma,Noriko Uemura,Kentaro Tanaka,Hiroki Mori,Mutsumi Okazaki

DOI: https://doi.org/10.1097/scs.0000000000009932

2024-01-17

Journal of Craniofacial Surgery

Abstract:Background: The widely used botox type A (BTX-A) is effective against synkinesis in facial palsy sequelae. Repeated injections are necessary and permanent improvements have been reported. We objectively evaluated the changes in synkinesis at >6 months after BTX-A injection, including changes over time with the number of administrations. Methods: In 48 patients who received multiple BTX-A injections, evaluation by the Sunnybrook Facial Grading System (FGS) and integrated electromyography (iEMG) was performed before treatment and at least 6 months after the first, second, and third BTX-A injection. The iEMG ratio on the affected and healthy sides was calculated for each mimetic muscle and mimic motion. Results: There was no significant difference in the FGS synkinesis score before treatment and after the third injection, although an improvement was observed. The iEMG ratio was significantly improved in the orbicularis oculi with open-mouth smile and lip pucker after the third dose compared to before treatment. The orbicularis oris showed a significant improvement when the eyelids were closed, while the platysma showed a significant improvement when the eyelids were closed and when the lip was pursed. Multiple regression analysis revealed that the orbicularis oculi and platysma had a greater effect on the iEMG ratio for the number of treatments than other factors. Conclusions: Repeated BTX-A injections showed improvements in synkinesis for the orbicularis oculi, orbicularis oris, and platysma, even after >6 months, compared to before treatment.

surgery
Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy

Hanganu Alexandru,Muthuraman Muthuraman,Venkata Chaitanya Chirumamilla,Nabin Koirala,Burcu Paktas,Günther Deuschl,Kirsten E Zeuner,Sergiu Groppa

DOI: https://doi.org/10.1371/journal.pone.0168652

IF: 3.7

2016-12-16

PLoS ONE

Abstract:Objective: Benign Essential Blepharospasm (BEB) and hemifacial spasm (HFS) are the most common hyperkinetic movement disorders of facial muscles. Although similar in clinical presentation different pathophysiological mechanisms are assumed. Botulinum Neurotoxin (BoNT) is a standard evidence-based treatment for both conditions. In this study we aimed to assess grey matter microstructural differences between these two groups of patients and compared them with healthy controls. In patients we furthermore tracked the longitudinal morphometric changes associated with BoNT therapy. We hypothesized microstructural differences between the groups at the time point of maximum symptoms representation and distinct longitudinal grey matter dynamics with symptom improvement. Methods: Cross-sectional and longitudinal analyses of 3T 3D-T1 MRI images from BEB, HFS patients prior to and one month after BoNT therapy and from a group of age and sex matched healthy controls. Cortical thickness as extracted from Freesurfer was assessed as parameter of microstructural integrity. Results: BoNT therapy markedly improved motor symptoms in patients with BEB and HFS. Significant differences of grey matter integrity have been found between the two patients groups. The BEB group showed lower cortical thickness at baseline in the frontal-rostral, supramarginal and temporal regions compared to patients with HFS. In this group BoNT treatment was associated with a cortical thinning in the primary motor cortex and the pre-supplementary motor area (pre-SMA). Contrary patients with HFS showed no longitudinal CT changes. A decreased cortical thickness was attested bilaterally in the temporal poles and in the right superior frontal region in BEB patients in comparison to HC. Patients in the HFS group presented a decreased CT in the left lingual gyrus and temporal pole. Conclusions: Although patients with BEB and HFS present clinically with involuntary movements of facial muscles, they exhibited differences in cortical thickness. While BoNT therapy was equally effective in both groups, widespread changes of cortical morphology occurred only in BEB patients. We demonstrated specific disease- and therapy-dependent structural changes induced by BoNT in the studied hyperkinetic conditions.
Intracranial foreign body.

C. Gökçek,Y. Erdem,Ender Köktekir,M. Karatay,M. A. Bayar,N. Edebali,C. Kiliç

2007-04-01

Turkish Neurosurgery

Abstract:Intracranial foreign bodies due to nonmissile intracranial penetrations occur rarely. Most of these penetrating injuries result from industrial accidents or criminal assaults. The complications which cause mortality in early stage are intracerebral hemorrhage, contusion, major vascular injury and meningitis. In case of such injuries, foreign bodies near the major vascular structures should not be attempted to taken out. Total excision of the foreign body via craniotomy should be planned and possible dural and vascular injuries should be repaired during surgery. Urgent surgery should be performed as there is 53% morbidity in case of late surgery and 62% morbidity in nonoperated cases. We herein report a 20-year old man who attempted suicide by introducing a nail into his brain and review the related literature.
Safety and Efficacy of Upper Eyelid Orbicularis Oculi Botulinum Toxin in Patients with Synkinesis

Aishwarya Shukla,Matthew Zhang,G Nina Lu

DOI: https://doi.org/10.1089/fpsam.2024.0026

2024-07-29

Abstract:Background: Chemodenervation is an important means of treating oral-ocular synkinesis, but upper eyelid treatment is avoided due to risk of blepharoptosis. Objective: To measure the change in eyelid position among patients with oral-ocular synkinesis who received botulinum toxin to the upper eyelid orbicularis oculi compared with those who received lateral and lower eyelid treatment alone. Methods: In this retrospective clinical study, patients were categorized as having received lateral and lower eyelid botulinum toxin alone or having received upper eyelid botulinum toxin (to the preseptal and orbital orbicularis oculi) along with lateral and lower eyelid treatment. Pre- and posttreatment margin to reflex distance 1 (MRD1), margin to reflex distance 2 (MRD2), and palpebral height were measured using Emotrics software and compared using t tests and regression analysis. Results: Twenty-five patients were included. Mean age was 48.7 years and 24% were male. Mean duration of paralysis was 29 months (range 9-360 months). Posttreatment resting MRD1 (3.36) was not significantly different than pretreatment resting MRD1 (3.43) for patients who received upper eyelid botulinum toxin (p value = 0.60). Conclusion: Botulinum toxin to the upper eyelid orbicularis oculi injected superficially in small, concentrated aliquots did not result in blepharoptosis and was effective in reducing oral-ocular synkinesis.
Positive effect of self-exercise following Botulinum toxin injection on the permanence of the recovery among the patients with HFS and BFS: A clinical trial

Ümmü Serpil Sari,Mehmet Eroglu,Gülseren Büyükşerbetçi,Figen Tokucoglu,Nilay Sahin

DOI: https://doi.org/10.1097/md.0000000000038215

IF: 1.6

2024-06-15

Medicine

Abstract:Hemifacial spasm (HFS) and blepharospasm (BFS) are the common clinical manifestations of the craniofacial region caused by spasms in the orbicularis oculi muscle innervated by the facial nerve. Although their pathogenesis is different, both are generally seen in women after the 4th and 5th decades. [ 1 ] The clinical presentation of HFS usually starts unilaterally from the orbicularis oculi muscle and spreads to the forehead, lower half of the face and the platysma over the years. Involuntary contractions can be observed in the orbicularis oculi, frontalis, zygomaticus major, zygomaticus minor, levator labii superioris, risorius, orbicularis oris, mentalis, and platysma muscles unilaterally or bilaterally. [ 2 ] BFS, on the other hand, starts with an increase in involuntary blinking and may result in the eyelid closure with involuntary contraction of the orbicularis oculi muscle. This contraction can even progress to functional blindness. [ 3 ] In patients with BFS, dystonia tends to spread to adjacent parts of the body (most commonly to the oromandibular and cervical regions) compared to patients with other focal dystonias. [ 4 ] In most of the cases, it is thought that the facial nerve is compressed by a vascular structure in the root exit zone region. [ 5 ] Although BFS was initially considered a basal ganglia disorder, accumulating neuroimaging evidence points to anatomical and functional involvement of various brain regions, including thalamus, lower brainstem, cerebellum, midbrain, and cortex. [ 6 ]

medicine, general & internal
Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatment

Yolanda Herrero-Infante,Ana Rodríguez-Sanz,Jorge Máñez-Miró,Francisco Vivancos-Matellano

DOI: https://doi.org/10.1016/j.clineuro.2021.106555

Abstract:Background: Hemifacial spasm (HFS) is an uncommon movement disorder characterized by involuntary contractions of muscles innervated by the facial nerve. The aim of this study is to analyze the etiology of HFS as well as the efficacy and safety of long-term botulinum toxin type A (BTX-A) treatment. Methods: Retrospective study including 125 patients with HFS treated with BTX-A from 1993 to 2019. Demographic and etiological variables as well as doses, number of sessions of BTX-A, infiltrated muscles, therapeutic response according to Patient Global Impression of Change Scale (PGIC-S), side effects and adjuvant treatments were analyzed. In addition, these variables were compared according to the etiology (idiopathic versus secondary). Results: 92 patients (73.6%) were women and the mean age at diagnosis was 58.63 years (SD 15.4). The etiology was idiopathic in 79 patients (63.2%), 17.6% were secondary to Bell's palsy, 14.4% to vascular compression and 2.4% to tumors. A higher total dose per session was observed in the secondary group. PGIC-S showed a good response in 96% of cases. 16 patients (12.8%) required pharmacological concomitant treatment. 59 patients (47.2%) developed side effects. Transient eyelid ptosis and facial weakness were the most common. Conclusions: The structural origin of a significant number of cases of HFS makes essential to complete an etiological diagnosis in all patients. In addition, the existence of a secondary cause could be associated with greater doses of BTX-A to achieve a good response. Regardless the etiology, long-term treatment with BTX-A in HFS is safe and effective.
Alexithymia Is Associated with Delayed Treatment Seeking in Acute Myocardial Infarction

Mg Carta,Federica Sancassiani,V. Pippia,K. Bhat,C. Sardu,L. Meloni

DOI: https://doi.org/10.1159/000341181

2013-03-28

Psychotherapy and Psychosomatics

Abstract:sations. Alexithymic trait scores were characterized using established classification scores (scores 6 61). Statistical analyses were carried out in a 2-step logistic regression approach. All possible factors were entered simultaneously in a single block. All 2-way interactions between the possible risk factors were included. To select significant interactions, a backward elimination procedure with a threshold of p ! 0.20 was used. The final sample included 83 patients, with 73.5% males. The mean time to treatment was 176.75 8 239.65 min. In the analyses, 36 patients (43.4%) were allocated to the cases, 47 patients (56.6%) to the controls. Table 1 lists the frequencies of factors concerning the awareness of the disease and care-seeking behavior. None of the possible confounding factors taken into account differed between cases and controls in a statistically significant manner. However, the association between alexithymia (OR for cases 3.7, 95% CI 1.3–10.1) and contact with primary care prior to hospitalization (OR for cases 3.5, 95% CI 1.3–9.3) was statistically significant. No difference was found between cases and controls with regard to diagnosis of lifetime anxiety and depression. The multivariate analysis confirms the differences indicated by the univariate model but the two factors did not show any interaction, since the copresence of the two risk factors produced a cumulative risk without significant amplification (OR approx. 15.5, 95% CI 2.85–84.6; p ! 0.0001). The study shows that low emotional awareness, measured by alexithymia, and having had contact with primary care were associated with increased time to treatment in STEMI. No interaction was found between the two factors. An early study of Kenyon et al. [6] found evidence that the presence of alexithymia predicted a delay in seeking treatment in AMI. A study of O’Carroll et al. [7] , 10 years later, found some differences in alexithymia when comparing a group of patients with AMI who were prompt care seekers ( ! 4 h), and a group of late AMI care seekers ( 1 4 h) but these differences did not reach the threshold for statistical significance. Even so the results of such studies are partially in agreement with our data; the extension of their study sample might have biased the results since STEMI is the severest form of AMI and the only in which the delay in medical intervention is currently known to be of great danger [2] . On the other hand, ours is the first report in the literature exploring alexithymia as a potential risk factor for delay in seeking care in STEMI and also the first study to divide cases and controls with the delayed time known to be associated with a poor outcome (2 h) [2] . Sociodemographic and clinical variables did not independently appear to explain the delay. These results partially confirm the previous findings [8] . However, there appears to be some contradictory findings concerning consultation with a primary care The elapsed time between a person experiencing pain or discomfort due to an acute myocardial infarction (AMI) with ST segment elevation (STEMI) and his/her arrival at a hospital seeking care is crucial for survival. In fact, the degree of myocardial necrosis is related to the length of the ischemic episode [1] , and survival depends on the early provision of reperfusion techniques. If reperfusion occurs within 2 h, some preservation of myocardial function is achieved; after this period, life expectancy or survival decreases drastically [2] . The most important factor impacting on longer time to treatment is the patient’s decision to delay seeking care [1] . Thus, psychological variables such as alexithymia influencing the decision may be relevant. Unfortunately many of the findings with respect to psychosocial factors in delayed care seeking are still controversial [3] . We sought to explore psychological factors that might explain the delay in seeking care in STEMI with particular attention to alexithymia. Consecutive patients aged 18–85 years, admitted to a Cardiology Ward at Cagliari University Hospital, from April 2010 to June 2011, diagnosed with STEMI according to the European Society of Cardiology guidelines [2] were eligible for this study. The study sample was divided based on ‘time to treatment’, defined as the interval between the onset of symptoms and the first diagnostic ECG: controls = early care-seeking patients ( ! 2 h); cases = late care-seeking patients ( 1 2 h). A form was to be filled in to record sociodemographic data, health service utilization and risk factors [4] ; the study adopted the nonpatient version of the SCID-I-DSM-IV [4] and the Italian version of the 20-item Toronto Alexithymia Scale (TAS-20) [5] , a self-reporting checklist measuring the ability to identify and describe feelings and to distinguish between feelings and bodily senReceived: February 27, 2012 Accepted after revision: June 16, 2012 Published online: March 28, 2013

Real-time impedance monitoring: a simple technique for a complex ablation.

Exploration of Effect and Dosage of Botulinum Toxin Type A for Long-Term Treatment of Idiopathic Blepharospasm

Clinical Observation of Treatment with Botulinum Toxin A for the Ipsilateral Tinnitus in Hemifaciai Spasm Patients

The Effect of Botulinum Neurotoxin A Injections on Meibomian Glands and Dry Eye

Improved Spiking Cortical Model Based Algorithm for Multi-focus Image Fusion

Ocular Surface Alterations in Blepharospasm Patients Treated with Botulinum Toxin a Injection

Treatment Effects of Botulinum Toxin Injection and Acupuncture on Blepharospasm Assessed by the Change in Lower Eyelid Tension

Study of the effect of botulinum toxin on electrophysiological monitoring during microvascular decomp-ression surgery for patients with hemifacial spasm

Non-surgical treatment of 150 cases of blepharospasm and hemifacial spasm

Correlation Between Blepharospasm and Psychological Diseases: the Anxiety, Depression and Sleep Disorder Study

Increasing the area and varying the dosage of Botulinum toxin a injections for effective treatment of hemifacial spasm

Evaluation of the effect of botulinum toxin A on the physical and mental health of patients with hemifacial spasm

Remote F - wave changes after local botulinum toxin type A application

Botulinum Toxin Injection with Conjunctival Microincision for the Treatment of Acute Acquired Comitant Esotropia and Its Effectiveness

Objective Assessment of the Repeated Botox Treatment to the Synkinesis of Facial Paralysis by the Integrated Electromyography

Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy

Intracranial foreign body.

Safety and Efficacy of Upper Eyelid Orbicularis Oculi Botulinum Toxin in Patients with Synkinesis

Positive effect of self-exercise following Botulinum toxin injection on the permanence of the recovery among the patients with HFS and BFS: A clinical trial

Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatment

Alexithymia Is Associated with Delayed Treatment Seeking in Acute Myocardial Infarction